Recent findings reveal the effect of two commonly used treatments on hepatitis C virus infection in individuals using drugs, usually by injection. The study compared the antiviral protocol sofosbuvir/velpatasvir, a combination therapy targeting the hepatitis B virus to prevent its replication and glecaprevir/pibrentasvir, another antiviral combination that also makes the virus in Another antiviral combination in the population that reproduces in vivo, challenges, provides realistic data on its safety and efficacy.
Researchers led by Dr. Brian Conway of the Vancouver Infectious Disease Center conducted the study in collaboration with Simon Fraser University, published in the Journal of Elimination of Viruses. Their study aims to determine whether one treatment is better than another in achieving hepatitis C virus treatment rates, measured by the lack of detectable viruses 12 or more weeks after treatment is completed.
The study evaluated an equal number of individuals in both treatment groups, both actively using or injecting medications. The results showed that both regimens achieved abnormally high treatment rates, with almost all participants successfully completing treatment. It is worth noting that both regimens are very effective even in people with significant health care disabilities such as unstable housing and concurrent use of fentanyl, which is disengaged from large amounts of drug overdose events and disengagement from care. Related powerful opioids.
A key finding was that most participants completed treatment, highlighting the importance of community-based healthcare support. “We found that participating in structured programs significantly improves adherence and outcomes, thus strengthening the need for accessible therapeutic strategies,” Dr. Conway said. Despite these interventions, participants still occurred during the study period,” Some drug-related deaths have been reported, which highlights the ongoing challenges of addiction and the need for comprehensive support programs designed to reduce health risks. Participation in programs such as those implemented by the Conway team has resulted in reducing the use of HRAM-reducing interventions, such as needle trading and monitoring drug use facilities, minimizing health risks to drug users.
It is important to note that participants using Glecaprevir and Pibrentasvir and Sofosbuvir and Velpatasvir showed the initial health and lifestyle factors of comparable studies, including comparisons used for the study, including local representation, housing instability, housing instability sex and fentanyl usage rate. The results of the study show that both treatments can be confidently delivered to the entire target population without worrying about significant differences in success rates or safety profiles.
With global efforts to eliminate HCV infections as a public health issue in 2030, this study highlights the importance of accessible treatment options and locally driven health care solutions. “Our data supports the provision of two treatment options in this vulnerable population, allowing us to ensure that we choose any option (a pill for 12 weeks a day with Sofosbuvir/Velpatasvir per day, or 3 pills per day or 3 weeks of Glecaprevir/Pibbrentasvir per day 8 weeks), this is a very effective treatment that will provide a regimen,” Dr. Conway concluded.
Journal Reference
Yi S., Truong D., Conway B. “Comparison of Sofosbuvir/velpatasvir and Glecaprevir/pibrentasvir for the treatment of hepatitis C infection in people with injected drugs.” Journal of Elimination of Virus, 2024. DOI: https://doi.org/10.1016/j.jve.2024.100388
About the Author
Dr. Brian Conway His career has been dedicated to transforming health care for marginalized and vulnerable communities in British Columbia. His work has greatly improved the care of French-speaking people and individuals affected by HIV and HCV. As medical director of the Vancouver Infectious Disease Center (VIDC), Dr. Conway pioneered the launching initiatives that enable academic research and patient-centered care. Through partnerships with pharmaceutical companies and research institutions, VIDC has become a hub for innovative treatments and compassionate people.
Dr. Conway’s work extends to Eastside in downtown Vancouver, where his weekly community pop-up clinic has tested thousands of HIV and HCV and is identified and identified through the Entente program (engagement, testing, interaction, treatment, participation) and It attracted many people. These efforts demonstrate his commitment to accessible healthcare.
Dr. Conway is widely recognized for his contributions, earning numerous honors, including the Elizabeth II Diamond Jubilee Medal, the Hepatitis Elimination Champion Award and the Science and Research Award.
Dr. Conway’s lifelong commitment to moving forward healthcare has left an indelible mark on British Columbia and fostered a healthier, more inclusive community.
